Fabry Disease – Epidemiology – Mature Markets (G7)
Clarivate Epidemiology’s coverage of Fabry disease comprises epidemiological estimates of key patient populations across the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report the prevalence of Fabry for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years.
Clarivate Epidemiology’s Fabry disease forecast will answer the following questions:
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of Fabry disease over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
In total, Clarivate Epidemiology forecasts one Fabry patient population, as follows:
- Diagnosed prevalent cases.
Kiranpreet Kaur, B.D.S., M.P.H., Epidemiologist, Epidemiology. Ms. Kaur received her master’s degree in public health (social epidemiology) from the Tata Institute of Social Sciences in Mumbai. She also holds a bachelor’s degree in dentistry from Panjab University.
Stephanie Niquita Phankon, M.B.B.S., M.P.H., Manager, Epidemiology. Ms. Phankon’s expertise is in autoimmune and inflammatory diseases and hematological malignancies. She holds a master’s in public health specializing in epidemiology from TISS in Mumbai and a medical degree from Hubei University of Chinese Medicine in the People’s Republic of China. She has been trained as a community physician and has supervised and coordinated various governmental and nongovernmental public health projects.